Inmune Bio, Inc.
INMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711754
No open-market purchases or sales by Inmune Bio, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $7.08M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Inmune Bio, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 41 | 41 | 0 |
| Shares | 1.74M | 1.94M | +205.1K (+11.8%) |
| Value | $30.6M | $37.7M | +$7.09M (+23.1%) |
New holders (9)
Institutions that held Inmune Bio, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| ACT Capital Management, LLC | 275,000 | $5.34M | 2.77% |
| Millennium Management LLC | 123,511 | $2.40M | 0.00% |
| Marshall Wace, LLP | 64,650 | $1.26M | 0.01% |
| DG Capital Management, LLC | 20,000 | $388.0K | 0.08% |
| Cubist Systematic Strategies, LLC | 19,989 | $388.0K | 0.00% |
| Susquehanna Fundamental Investments, LLC | 17,200 | $334.0K | 0.01% |
| Kelly Financial Services LLC | 2,000 | $38.8K | 0.02% |
| Migdal Insurance & Financial Holdings Ltd. | 1,608 | $31.0K | 0.00% |
| Leonteq Securities AG | 1,300 | $25.2K | 0.00% |
Sold out (9)
Institutions that held Inmune Bio, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| EAM Investors, LLC | 161,793 | $2.84M |
| EAM Global Investors LLC | 116,809 | $2.05M |
| Altium Capital Management LP | 52,257 | $918.0K |
| Boothbay Fund Management, LLC | 24,158 | $424.0K |
| Virtu Financial LLC | 10,530 | $185.0K |
| Marino, Stram & Associates LLC | 10,369 | $182.0K |
| Advisory Services Network, LLC | 3,108 | $55.0K |
| Tower Research Capital LLC (TRC) | 1,401 | $25.0K |
| FFT Wealth Management LLC | 25 | $0 |